Growth Metrics

Travere Therapeutics (TVTX) Gains from Investment Securities (2016 - 2025)

Travere Therapeutics' Gains from Investment Securities history spans 13 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 62.49% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $404000.0, up 105.09%, while the annual FY2025 figure was $404000.0, 105.09% up from the prior year.
  • Gains from Investment Securities reached -$1.1 million in Q4 2025 per TVTX's latest filing, down from $1.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $13.9 million in Q3 2021 to a low of -$11.4 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $412263.2, with a median of $328000.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: crashed 390.76% in 2024, then skyrocketed 376.52% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$11.4 million in 2021, then surged by 155.94% to $6.4 million in 2022, then plummeted by 180.76% to -$5.1 million in 2023, then skyrocketed by 43.23% to -$2.9 million in 2024, then skyrocketed by 62.49% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Gains from Investment Securities are -$1.1 million (Q4 2025), $1.6 million (Q3 2025), and -$146000.0 (Q2 2025).